Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. J. Barrett
Development of Engineered T Cells Expressing a Chimeric CD16-CD3 Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Clinical Cancer Research
Cancer Research
Oncology
Clinics in Haematology. Vol 10 No. 1 Feb. 1981 Enzymopathies
Postgraduate Medical Journal
Medicine
Related publications
High-Affinity CD16-polymorphism and Fc-Engineered Antibodies Enable Activity of CD16-chimeric Antigen Receptor-Modified T Cells for Cancer Therapy
British Journal of Cancer
Cancer Research
Oncology
Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Immunotherapy
Oncology
Allergy
Immunology
Genetically Engineered T Cells Expressing a HER2-specific Chimeric Receptor Mediate Antigen-Specific Tumor Regression
Cancer Gene Therapy
Cancer Research
Molecular Medicine
Molecular Biology
768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells
Journal of Immunology
Allergy
Immunology
CML Hematopoietic Stem Cells Expressing IL-1RAP Can Be Targeted by Chimeric Antigen Receptor (CAR)-engineered T Cells
Cancer Research
Cancer Research
Oncology
Pre-Clinical Evaluation of CD38 Chimeric Antigen Receptor Engineered T Cells for the Treatment of Multiple Myeloma
Haematologica
Hematology
CD3 Down-Regulating Factor in Patients With Adult T Cell Leukemia.
Japanese Journal of Clinical Immunology
Development of a Wilms' Tumor Antigen-Specific T-Cell Receptor for Clinical Trials: Engineered Patient's T Cells Can Eliminate Autologous Leukemia Blasts in NOD/SCID Mice
Haematologica
Hematology
